Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bioniche Life Sciences has announced the termination of the Phase III non-muscle-invasive bladder cancer trial with Urocidin.
Subscribe to our email newsletter
Endo Pharmaceuticals, Bioniche’s licensing partner, was conducting the randomized, active-controlled trial.
According to Bioniche, the study was not being recruited at the anticipated rate and subsequent to the discussions with FDA about the trial design, Endo resolved to terminate the study.
The open-label, multi-center study was designed to compare Urocidin with mitomycin C in the intravesical treatment of BCG recurrent or refractory non-muscle-invasive bladder cancer patients.
Bioniche Life Sciences president and CEO Graeme McRae said the discontinuation of the trial is the best decision given the circumstances.
"We are working with Endo to determine the next steps for the Urocidin clinical program in order to build on the successful outcome of the first Phase III trial and to continue to work toward regulatory approval for this important and much-needed therapy," McRaea added.
Both the companies are working together to determine the next steps for the Urocidin clinical program.